Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Results Conference Call March 13, 2024 5:00 PM ET

Company Participants

Jamie Taylor - Head of Investor Relations

Dennis Lanfear - Chief Executive Officer

Paul Reider - Chief Commercial Officer

Rosh Dias - Chief Medical Officer

Theresa LaVallee - Chief Development Officer

Bryan McMichael - Interim Chief Financial Officer

Conference Call Participants

Yigal Nochomovitz - Citigroup

Colleen Kusy - Baird

Michael Nedelcovych - TD Cowen

Ethan Brown - JPMorgan

Operator

Good day, and thank you for standing by. Welcome to the Q4 2023 Coherus BioSciences, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Jamie Taylor, Head of Investor Relations for Coherus.

Jamie Taylor

Thank you, operator. Good afternoon, and welcome to Coherus BioSciences fourth quarter and full-year 2023 earnings conference call. Joining me today to discuss our results are Denny Lanfear, Chief Executive Officer of Coherus; Bryan McMichael, Interim Chief Financial Officer; Paul Reider, Chief Commercial Officer; Rosh Dias, Chief Medical Officer; and Theresa LaVallee, Chief Development Officer.

Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherus’ current expectations about future events. These statements include, but are not limited to, the following: Our ability to advance our pipeline, projections of future growth, revenue, expenses, headcount, and debt levels, and the timing of any return to profitability or cash flow positivity. All of these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance, or achievements to differ from those implied by the forward-looking statements.

These statements are not guarantees to future performance and are subject to substantial risks and uncertainties, including risks and uncertainties inherent in the clinical drug development process that are discussed in our press release that we issued today, as well as the documents that we file with the SEC. Forward-looking statements provided on the call today are made as of this date and we undertake no duty to update or revise any forward-looking statement.

With that, I'll turn the call over to Denny.

Dennis Lanfear

Thanks, Jamie, and thank you all for joining us on the call today. I'm pleased to report to you today's strong fourth quarter results, rounding out an important year of transition for Coherus, as we sharpened our focus on innovative oncology, positioning the company for new levels of efficiency and growth in 2024 and beyond. Our strategy and our mission are clear to extend the lives of cancer patients.